Artificial Intelligence Guided Echocardiographic Screening of Rare Diseases (EchoNet-Screening)

Launched by CEDARS-SINAI MEDICAL CENTER · Nov 30, 2021

Keywords

ClinConnect Summary

The EchoNet-Screening trial is studying a new approach to help detect a heart condition called cardiac amyloidosis, which can be difficult to identify. Researchers have developed a special computer program, called EchoNet-LVH, that uses advanced technology to analyze heart images. This program aims to find signs of heart thickening that may indicate the need for further testing for cardiac amyloidosis. By using this technology, the goal is to improve the accuracy of identifying patients who might benefit from additional screening.

Patients aged 65 and older who have a high suspicion of cardiac amyloidosis, as determined by the AI program, may be eligible to participate in this study. If you join the trial, you can expect to have your heart images evaluated by the AI program to see if further testing is needed. It's important to know that patients who choose not to visit the specialty clinic or those who have passed away cannot participate. This trial is currently recruiting participants, and it offers a potential way to enhance the early detection and treatment of this rare heart condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients who have a high suspicion for cardiac amyloidosis by AI algorithm
• Exclusion Criteria:
• • Patients who decline to be seen at specialty clinic
• • Patients who have passed away